Mithra Signs Agreement for Commercialization of Myring™ in China with Abbott

  • Mithra grants an exclusive license for commercialization of vaginal contraceptive ring in China
  • The introduction of a long acting contraceptive method represents a compelling new alternative for women in China

Liege, Belgium, 14 October 2019, 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into an exclusive license and commercialization agreement with Abbott for the registration and launch of its hormonal contraceptive ring Myring™ in China.